Abstract
Lung cancer is the most common cancer worldwide. Approximately 18% of all deaths related to cancer are associated with lung cancer. Management of non-small cell lung cancer (NSCLC) has been changing rapidly in last few years. For patients with unresectable non-metastatic disease, maintenance durvalumab is now given after offering chemo-radiation concurrently based on the result from the PACIFIC trial. Management of metastatic disease greatly depends on the status of sensitizing driver mutation and PDL1 level of the tumor cells. In this review article, we will summarize the outcome of various clinical trials and will provide the most up-to-date information on the management of patients with advanced and metastatic NSCLC.
Original language | English (US) |
---|---|
Pages (from-to) | 6992-7001 |
Number of pages | 10 |
Journal | Journal of Thoracic Disease |
Volume | 12 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2020 |
Keywords
- Advanced
- Lung cancer
- Metastatic
- Non-small cell lung cancer (NSCLC)
- Stage III
- Stage IV
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine